GenKyoTex raises CHF18 million as lead anti-ROS candidate ready for clinic
This article was originally published in Scrip
Executive Summary
GenKyoTex, a French/Swiss biotechnology company, has raised CHF18 million ($20.4 million) in a series C round led by Edmond de Rothschild Investment Partners (EdRIP).